Practice bulletin No. 119: Female sexual dysfunction

Obstetrics and Gynecology

Volumn 117, Issue 4, 2011, Pages 996-1007

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANAMNESIS; ANXIETY; ARTICLE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISTRESS SYNDROME; DOCTOR PATIENT RELATION; FEMALE; FEMALE SEXUAL DYSFUNCTION; HUMAN; HUMAN RELATION; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; SYMPTOM; GYNECOLOGY; INCIDENCE; MEDICAL SOCIETY; OBSTETRICS; PRACTICE GUIDELINE; PROGNOSIS; PSYCHOSEXUAL DISORDER; REVIEW; RISK ASSESSMENT; SEXUAL DYSFUNCTION; STANDARD; TREATMENT OUTCOME; UNITED STATES;

FEMALE; GYNECOLOGY; HUMANS; INCIDENCE; OBSTETRICS; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RISK ASSESSMENT; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; SOCIETIES, MEDICAL; TREATMENT OUTCOME; UNITED STATES;

EID: 79953201202     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e31821921ce     Document Type: Article

References (100)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Text rev. Washington, DC: APA; 2000. (Level III)
2. Basson R. Sexuality and sexual disorders. Clin Update Womens Health Care 2003;II(2):1-94. (Level III)
3. Kingsberg SA. Taking a sexual history. Obstet Gynecol Clin North Am 2006;33:535-47. (Level III) (Pubitemid 44751392)
4. Kinsey AC. Sexual behavior in the human female. Philadelphia (PA): Saunders; 1953. (Level III)
5. Masters WH, Johnson VE. Human sexual response. Boston (MA): Little, Brown and Company; 1966. (Level III)
6. Kaplan HS. Disorders of sexual desire and other new concepts and techniques in sex therapy. New York (NY): Simon and Schuster; 1979. (Level III)
7. Davis SR, Guay AT, Shifren JL, Mazer NA. Endocrine aspects of female sexual dysfunction. J Sex Med 2004; 1:82-6. (Level III) (Pubitemid 40424670)
8. Archer JS, Love-Geffen TE, Herbst-Damm KL, Swinney DA, Chang JR. Effect of estradiol versus estradiol and testosterone on brain-activation patterns in postmenopausal women. Menopause 2006;13:528-37. (Level III)
9. Gizewski ER, Krause E, Karama S, Baars A, Senf W, Forsting M. There are differences in cerebral activation between females in distinct menstrual phases during viewing of erotic stimuli: a fMRI study. Exp Brain Res 2006;174:101-8. (Level II-3) (Pubitemid 44337551)
10. Bartels A, Zeki S. The neural correlates of maternal and romantic love. Neuroimage 2004;21:1155-66. (Level III) (Pubitemid 38314977)
11. Lorrain DS, Riolo JV, Matuszewich L, Hull EM. Lateral hypothalamic serotonin inhibits nucleus accumbens dopamine: implications for sexual satiety. J Neurosci 1999;19:7648-52. (Level III) (Pubitemid 29404620)
12. Abraham GE. Ovarian and adrenal contribution to peripheral androgens during the menstrual cycle. J Clin Endocrinol Metab 1974;39:340-6. (Level III)
13. Jeong GW, Park K, Youn G, Kang HK, Kim HJ, Seo JJ, et al. Assessment of cerebrocortical regions associated with sexual arousal in premenopausal and menopausal women by using BOLD-based functional MRI. J Sex Med 2005;2:645-51. (Level II-3) (Pubitemid 41742924)
14. Exton MS, Bindert A, Kruger T, Scheller F, Hartmann U, Schedlowski M. Cardiovascular and endocrine alterations after masturbation-induced orgasm in women. Psychosom Med 1999;61:280-9. (Level III)
15. Meston CM, Levin RJ, Sipski ML, Hull EM, Heiman JR. Women's orgasm. Annu Rev Sex Res 2004;15:173-257. (Level III) (Pubitemid 41422840)
16. Shifren JL, Schiff I. Role of hormone therapy in the management of menopause. Obstet Gynecol 2010;115:839-55. (Level III)
17. Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol 2008;112:970-8. (Level II-3)
18. Segraves R, Woodard T. Female hypoactive sexual desire disorder: History and current status. J Sex Med 2006;3:408-18. (Level III)
19. West SL, D'Aloisio AA, Agans RP, Kalsbeek WD, Borisov NN, Thorp JM. Prevalence of low sexual desire and hypoactive sexual desire disorder in a nationally representative sample of US women. Arch Intern Med 2008;168:1441-9. (Level II-3) (Pubitemid 352008425)
20. Orentreich N, Brind JL, Rizer RL, Vogelman JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab 1984;59:551-5. (Level II-3) (Pubitemid 14031806)
21. Rotter JI, Wong FL, Lifrak ET, Parker LN. A genetic component to the variation of dehydroepiandrosterone sulfate. Metabolism 1985;34:731-6. (Level III) (Pubitemid 15018614)
22. Crawford S, Santoro N, Laughlin GA, Sowers MF, McConnell D, Sutton-Tyrrell K, et al. Circulating dehy droepiandrosterone sulfate concentrations during the menopausal transition. J Clin Endocrinol Metab 2009;94: 2945-51. (Level II-2)
23. Labrie F, Belanger A, Cusan L, Gomez JL, Candas B. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J Clin Endocrinol Metab 1997;82: 2396-402. (Level III) (Pubitemid 27337846)
24. Hornsby PJ. Biosynthesis of DHEAS by the human adrenal cortex and its age-related decline. Ann N Y Acad Sci 1995;774:29-46. (Level III) (Pubitemid 26140358)
25. Dennerstein L, Randolph J, Taffe J, Dudley E, Burger H. Hormones, mood, sexuality, and the menopausal transition. Fertil Steril 2002;77 (suppl 4):S42-8. (Level II-2) (Pubitemid 34465843)
26. Dennerstein L, Koochaki P, Barton I, Graziottin A. Hypoactive sexual desire disorder in menopausal women: a survey of Western European women. J Sex Med 2006; 3:212-22. (Level II-3)
27. Johannsson G, Burman P, Wiren L, Engstrom BE, Nilsson AG, Ottosson M, et al. Low dose dehydroepiandrosterone affects behavior in hypopituitary androgendeficient women: a placebo-controlled trial. J Clin Endocrinol Metab 2002;87:2046-52. (Level I) (Pubitemid 34525078)
28. Zang H, Davis SR. Androgen replacement therapy in androgen-deficient women with hypopituitarism. Drugs 2008;68:2085-93. (Level III)
29. Davis AR, Castano PM. Oral contraceptives and libido in women. Annu Rev Sex Res 2004;15:297-320. (Level III) (Pubitemid 41422842)
30. Stimmel GL, Gutierrez MA. Sexual dysfunction and psychotropic medications. CNS Spectr 2006;11:24-30. (Level III) (Pubitemid 44273472)
31. Montejo-Gonzalez AL, Llorca G, Izquierdo JA, Ledesma A, Bousono M, Calcedo A, et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther 1997; 23:176-94. (Level II-3) (Pubitemid 27514710)
32. Caruso S, Intelisano G, Lupo L, Agnello C. Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, cross-over, placebo-controlled study. BJOG 2001;108:623-8. (Level II-3) (Pubitemid 33646504)
33. Basson R. Female sexual response: the role of drugs in the management of sexual dysfunction [published erratum appears in Obstet Gynecol 2001;98:522]. Obstet Gynecol 2001;98:350-3. (Level III)
34. Kingsberg SA, Janata JW. Female sexual disorders: assessment, diagnosis, and treatment. Urol Clin North Am 2007;34:497-506, v-vi. (Level III) (Pubitemid 350029956)
35. Graziottin A. Iatrogenic and post-traumatic female sexual disorder. In: Porst H, Buvat J, editors. Standard practice in sexual medicine. Malden (MA): Blackwell; 2006. p. 351-61. (Level III)
36. Kennedy SH, Rizvi S. Sexual dysfunction, depression, and the impact of antidepressants. J Clin Psychopharmacol 2009;29:157-64. (Level III)
37. Dunn KM, Cherkas LF, Spector TD. Genetic influences on variation in female orgasmic function: a twin study. Biol Lett 2005;1:260-3. (Level II-3) (Pubitemid 41374878)
38. Binik YM, Reissing E, Pukall C, Flory N, Payne KA, Khalife S. The female sexual pain disorders: genital pain or sexual dysfunction? Arch Sex Behav 2002;31:425-9. (Level III) (Pubitemid 38471086)
39. McCabe MP. Anorgasmia in women. J Fam Psychother 2009;20:177-97. (Level III)
40. Steege JF, Zolnoun DA. Evaluation and treatment of dyspareunia. Obstet Gynecol. 2009;113:1124-36. (Level III)
41. Latthe P, Mignini L, Gray R, Hills R, Khan K. Factors predisposing women to chronic pelvic pain: systematic review. BMJ 2006;332:749-55. (Systematic Review)
42. Risen CB. A guide to taking a sexual history. Psychiatr Clin North Am 1995;18:39-53. (Level III)
43. Hatzichristou D, Rosen RC, Derogatis LR, Low WY, Meuleman EJ, Sadovsky R, et al. Recommendations for the clinical evaluation of men and women with sexual dysfunction. J Sex Med 2010;7:337-48. (Level III)
44. Tomlinson J. ABC of sexual health: taking a sexual history. BMJ 1998;317:1573-6. (Level III) (Pubitemid 28550244)
45. Kingsberg S. Just ask! Talking to patients about sexual function. Sex Reprod Menopause 2004;2:199-203. (Level III) (Pubitemid 40260284)
46. Hensley PL, Nurnberg HG. SSRI sexual dysfunction: a female perspective. J Sex Marital Ther 2002;28(suppl 1): 143-53. (Level III) (Pubitemid 34202985)
47. Falcone T, Walters MD. Hysterectomy for benign disease. Obstet Gynecol 2008;111:753-67. (Level III) (Pubitemid 351654083)
48. Lalinec-Michaud M, Engelsmann F. Anxiety, fears and depression related to hysterectomy. Can J Psychiatry 1985; 30:44-7. (Level III) (Pubitemid 15146375)
49. Dennerstein L, Wood C, Burrows GD. Sexual response following hysterectomy and oophorectomy. Obstet Gynecol 1977;49:92-6. (Level III) (Pubitemid 8034070)
50. Jewett JG. Vaginal length and incidence of dyspareunia following total abdominal hysterectomy. Am J Obstet Gynecol 1952;63:400-7. (Level III)
51. Kilkku P, Gronroos M, Hirvonen T, Rauramo L. Supravaginal uterine amputation vs. hysterectomy. Effects on libido and orgasm. Acta Obstet Gynecol Scand 1983;62 147-52. (Level II-3) (Pubitemid 13100260)
52. Oldenhave A, Jaszmann LJ, Haspels AA, Everaerd WT. Impact of climacteric on well-being. A survey based on 5213 women 39 to 60 years old. Am J Obstet Gynecol 1993;168:772-80. (Level II-3) (Pubitemid 23095992)
53. Kilkku P. Supravaginal uterine amputation vs. hysterectomy. Effects on coital frequency and dyspareunia. Acta Obstet Gynecol Scand 1983;62:141-5. (Level II-3) (Pubitemid 13100259)
54. Virtanen H, Makinen J, Tenho T, Kiilholma P, Pitkanen Y, Hirvonen T. Effects of abdominal hysterectomy on urinary and sexual symptoms. Br J Urol 1993;72:868-72. (Level III) (Pubitemid 24053504)
55. Helstrom L, Lundberg PO, Sorbom D, Backstrom T. Sexuality after hysterectomy: a factor analysis of women's sexual lives before and after subtotal hysterectomy. Obstet Gynecol 1993;81:357-62. (Level II-3) (Pubitemid 23085290)
56. Rhodes JC, Kjerulff KH, Langenberg PW, Guzinski GM. Hysterectomy and sexual functioning. JAMA 1999;282: 1934-41. (Level II-2)
57. Zobbe V, Gimbel H, Andersen BM, Filtenborg T, Jakobsen K, Sorensen HC, et al. Sexuality after total vs. subtotal hysterectomy. Acta Obstet Gynecol Scand 2004; 83:191-6.( Level I) (Pubitemid 38234057)
58. Thakar R, Ayers S, Clarkson P, Stanton S, Manyonda I. Outcomes after total versus subtotal abdominal hysterectomy. N Engl J Med 2002;347:1318-25.( Level I) (Pubitemid 35215322)
59. Gimbel H, Zobbe V, Andersen BM, Filtenborg T, Gluud C, Tabor A. Randomised controlled trial of total compared with subtotal hysterectomy with one-year follow up results. BJOG 2003;110:1088-98. (Level I) (Pubitemid 37510151)
60. Kuppermann M, Summitt RL Jr, Varner RE, McNeeley SG, Goodman-Gruen D, Learman LA, et al. Sexual functioning after total compared with supracervical hysterectomy: a randomized trial. Total or Supracervical Hysterectomy Research Group. Obstet Gynecol 2005;105:1309-18. (Level I) (Pubitemid 40734262)
61. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. Writing Group for the Women's Health Initiative Investigators. JAMA 2002; 288:321-33. (Level 1) (Pubitemid 34761611)
62. Gorodeski GI. Aging and estrogen effects on transcervical- transvaginal epithelial permeability. J Clin Endocrinol Metab 2005;90:345-51. (Level III) (Pubitemid 40116680)
63. Ayton RA, Darling GM, Murkies AL, Farrell EA, Weisberg E, Selinus I, et al. A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy. Br J Obstet Gynaecol 1996; 103:351-8. (Level I) (Pubitemid 26106031)
64. Berman JR, Berman L, Goldstein I. Female sexual dysfunction: incidence, pathophysiology, evaluation, and treatment options. Urology 1999;54:385-91. (Level III) (Pubitemid 29407007)
65. Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc 2010;85:87-94. (Level III)
66. Lara LA, Useche B, Ferriani RA, Reis RM, de Sa MF, de Freitas MM, et al. The effects of hypoestrogenism on the vaginal wall: interference with the normal sexual response. J Sex Med 2009;6:30-9. (Level III)
67. Suckling JA, Kennedy R, Lethaby A, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD001500. DOI: 10.1002/14651858.CD001500. pub2. (Meta-analysis)
68. Notelovitz M, Funk S, Nanavati N, Mazzeo M. Estradiol absorption from vaginal tablets in postmenopausal women. Obstet Gynecol 2002;99:556-62. (Level I) (Pubitemid 34246288)
69. Bachmann GA. Influence of menopause on sexuality. Int J Fertil Menopausal Stud 1995;40(suppl 1):16-22. (Level III)
70. Berman JR, Berman LA, Toler SM, Gill J, Haughie S. Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: a double-blind, placebo controlled study. Sildenafil Study Group. J Urol 2003;170:2333-8. ( Level I) (Pubitemid 37413990)
71. Basson R, McInnes R, Smith MD, Hodgson G, Koppiker N. Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder. J Womens Health Gend Based Med 2002; 11:367-77.( Level I)
72. Basson R, Brotto LA. Sexual psychophysiology and effects of sildenafil citrate in oestrogenised women with acquired genital arousal disorder and impaired orgasm: a randomised controlled trial. BJOG 2003;110:1014-24. (Level I) (Pubitemid 37338491)
73. Nurnberg HG, Hensley PL, Heiman JR, Croft HA, Debattista C, Paine S. Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial. JAMA 2008;300:395-404. (Level I) (Pubitemid 352040251)
74. Wilson SK, Delk JR 2nd, Billups KL. Treating symptoms of female sexual arousal disorder with the Eros-Clitoral Therapy Device. J Gend Specif Med 2001;4:54-8. (Level III) (Pubitemid 34023964)
75. Billups KL. The role of mechanical devices in treating female sexual dysfunction and enhancing the female sexual response. World J Urol 2002;20:137-41. (Level III)
76. Burger HG, Papalia MA. A clinical update on female androgen insufficiency-testosterone testing and treatment in women presenting with low sexual desire. Sex Health 2006;3:73-8. (Level III) (Pubitemid 43829302)
77. Davison SL, Bell R, Donath S, Montalto JG, Davis SR. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 2005;90:3847-53. (Level II-3) (Pubitemid 41058142)
78. Braunstein GD, Sundwall DA, Katz M, Shifren JL, Buster JE, Simon JA, et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch Intern Med 2005;165: 1582-9. (Level I) (Pubitemid 41124151)
79. Braunstein GD. Safety of testosterone treatment in postmenopausal women. Fertil Steril 2007;88:1-17. (Level III) (Pubitemid 47001404)
80. Braunstein GD. Management of female sexual dysfunction in postmenopausal women by testosterone administration: safety issues and controversies. J Sex Med 2007; 4:859-66. (Level III) (Pubitemid 47079624)
81. Buster JE, Kingsberg SA, Aguirre O, Brown C, Breaux JG, Buch A, et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol 2005;105:944-52. (Level I) (Pubitemid 40571010)
82. Simon J, Braunstein G, Nachtigall L, Utian W, Katz M, Miller S, et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005;90:5226-33. (Level I) (Pubitemid 41262278)
83. Davis SR, van der Mooren MJ, van Lunsen RH, Lopes P, Ribot C, Rees M, et al. Efficacy and safety of a testoster one patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial [published erratum appears in Menopause 2006;13:850]. Menopause 2006;13:387-96. (Level I)
84. Shifren JL, Davis SR, Moreau M, Waldbaum A, Bouchard C, DeRogatis L, et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study [published erratum appears in Menopause 2007;14:157]. Menopause 2006;13:770-9.( Level I)
85. Davis SR, McCloud P, Strauss BJ, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 2008;61:17-26. (Level I)
86. Davis SR, Moreau M, Kroll R, Bouchard C, Panay N, Gass M, et al. Testosterone for low libido in postmenopausal women not taking estrogen. APHRODITE Study Team. N Engl J Med 2008;359:2005-17. (Level I)
87. Nachtigall L, Casson P, Lucas J, Schofield V, Melson C, Simon JA. Safety and tolerability of testosterone patch therapy for up to 4 years in surgically menopausal women receiving oral or transdermal oestrogen. Gynecol Endocrinol 2011;27:39-48. (Level I)
88. The role of testosterone therapy in postmenopausal women: position statement of The North American Menopause Society. North American Menopause Society. Menopause 2005;12:496-511; quiz 649. (Level III)
89. Wierman ME, Basson R, Davis SR, Khosla S, Miller KK, Rosner W, et al. Androgen therapy in women: an Endocrine Society Clinical Practice guideline. J Clin Endocrinol Metab 2006;91:3697-710. (Level III) (Pubitemid 44536831)
90. Seibel MM. Men, women, and testosterone: why did the FDA fail Intrinsa? Sex Reprod Menopause 2005;3:1-2. (Level III) (Pubitemid 40862371)
91. Goldstat R, Briganti E, Tran J, Wolfe R, Davis SR. Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. Menopause 2003;10:390-8. (Level II-3)
92. Davis S, Papalia MA, Norman RJ, O'Neill S, Redelman M, Williamson M, et al. Safety and efficacy of a testosterone metered-dose transdermal spray for treating decreased sexual satisfaction in premenopausal women: a randomized trial. Ann Intern Med 2008;148:569-77. (Level I) (Pubitemid 351669130)
93. Lobo RA, Rosen RC, Yang HM, Block B, Van Der Hoop RG. Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. Fertil Steril 2003;79: 1341-52. (Level I) (Pubitemid 36687880)
94. Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, et al. High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy. Gynecol Endocrinol 2010;26:524-32. (Level I)
95. Sherwin BB. Use of combined estrogen-androgen preparations in the postmenopause: evidence from clinical studies. Int J Fertil Womens Med 1998;43:98-103. (Level III)
96. Barrett-Connor E, Timmons C, Young R, Wiita B. Interim safety analysis of a two-year study comparing oral estrogen-androgen and conjugated estrogens in surgically menopausal women. Estratest Working Group. J Womens Health 1996;5:593-602. (Level III) (Pubitemid 27045917)
97. Urman B, Pride SM, Yuen BH. Elevated serum testosterone, hirsutism, and virilism associated with combined androgen-estrogen hormone replacement therapy. Obstet Gynecol 1991;77:595-8. (Level III)
98. Chiuve SE, Martin LA, Campos H, Sacks FM. Effect of the combination of methyltestosterone and esterified estrogens compared with esterified estrogens alone on apolipoprotein CIII and other apolipoproteins in very low density, low density, and high density lipoproteins in surgically postmenopausal women. J Clin Endocrinol Metab 2004;89:2207-13. (Level I) (Pubitemid 38619854)
99. van Kesteren PJ, Asscheman H, Megens JA, Gooren LJ. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol 1997;47: 337-42. (Level II-3) (Pubitemid 27395966)
100. Ness RB, Albano JD, McTiernan A, Cauley JA. Influence of estrogen plus testosterone supplementation on breast cancer. Arch Intern Med 2009;169:41-6. (Level II-2)